P K. Epling-Burnette
Affiliations: | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Immunology, Oncology, Cell BiologyGoogle:
"P Epling-Burnette"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Elmarsafawi AG, Hesterberg RS, Fernandez MR, et al. (2023) Modulating the polyamine-hypusine axis controls generation of CD8+ tissue resident memory T cells. Jci Insight |
| Mhibik M, Gaglione EM, Eik D, et al. (2023) Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or Bcl-2 targeting. Blood Advances |
| Hesterberg RS, Beatty MS, Han Y, et al. (2020) Cereblon Harnesses Myc-Dependent Bioenergetics and Activity of CD8+ T lymphocytes. Blood |
| Zhang Q, Haider M, Al Ali NH, et al. (2020) SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia |
| Rollison DE, Fenske NA, Cherpelis B, et al. (2020) Abstract 3492: Circulating immunosuppressive regulatory T cells and risk of incident cutaneous squamous cell carcinoma Epidemiology. 80: 3492-3492 |
| Yue L, Sharma V, Horvat NP, et al. (2019) HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood |
| Mazzacurati L, Collins RJ, Pandey G, et al. (2019) The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Advances. 3: 3503-3514 |
| Sekeres MA, Gore SD, Stablein DM, et al. (2019) The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia & Lymphoma. 1-11 |
| Park DS, Akuffo AA, Muench DE, et al. (2019) Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation. Plos Computational Biology. 15: e1006913 |
| Pandey G, Horvat N, Amin NE, et al. (2019) RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms Blood. 134: 4198-4198 |